First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

• Main Authors: Rupa Narayan (Author), Ana Alfonso Piérola (Author), William B. Donnellan (Author), Antonieta Molero Yordi (Author), Maher Abdul‐Hay (Author), Uwe Platzbecker (Author), Marion Subklewe (Author), Tapan Mahendra Kadia (Author), Juan Manuel Alonso‐Domínguez (Author), James McCloskey (Author), Kathryn Bradford (Author), Martin Curtis (Author), Nikki Daskalakis (Author), Christina Guttke (Author), Karim Safer (Author), Brett Hiebert (Author), Joseph Murphy (Author), Xiang Li (Author), Ken Duchin (Author), Daniel Esteban (Author)
• Format: Book
• Published: Wiley, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ‐67571244, was assessed to identify the maximum tolerated dose (MTD), recommended phase II dose (RP2D),...